Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neoplasia
Auteurs principaux: Jacobsen, Frank, Kraft, Juliane, Schroeder, Cornelia, Hube-Magg, Claudia, Kluth, Martina, Lang, Dagmar S., Simon, Ronald, Sauter, Guido, Izbicki, Jakob R., Clauditz, Till S., Luebke, Andreas M., Hinsch, Andrea, Wilczak, Waldemar, Wittmer, Corinna, Büscheck, Franziska, Höflmayer, Doris, Minner, Sarah, Tsourlakis, Maria Christina, Huland, Hartwig, Graefen, Markus, Budäus, Lars, Thederan, Imke, Salomon, Georg, Schlomm, Thorsten, Melling, Nathaniel
Format: Artigo
Langue:Inglês
Publié: Neoplasia Press 2017
Sujets:
Original article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5565634/
https://ncbi.nlm.nih.gov/pubmed/28830008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2017.06.003
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires